Global /Taiwan /Healthcare /Biotechnology /7754

AnnJi Pharmaceutical Co., Ltd.

7754

• TPEX: 7754 • Delayed

62.00TWD -1.4%

1.96 USD

As of 21 June 2026, AnnJi Pharmaceutical Co., Ltd. has a market cap of $187.11M USD, ranking #21509 globally and #1001 in Taiwan. It ranks #1918 in the Healthcare sector, and #374 in the Biotechnology industry.

Global Rank

21509

Country Rank

1001

Sector Rank

1918

Industry Rank

374

Key Stats

Market Cap

$187.11MUSD

5.92B TWD

Enterprise Value

$177.55MUSD

5.62B TWD

Revenue (TTM)

$238.82KUSD

7.55M TWD

EBITDA (TTM)

-$10.49MUSD

-331.86M TWD

Net Income (TTM)

-$11.32MUSD

-357.87M TWD

PS Ratio

783.5

PB Ratio

18.5

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Wenying Huang open_in_new

Founded

2014

Website

ajpharm.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.4%	-5.1%	-2.2%	23%	28%	21%	183%	2%	2%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	7754 安基生技新藥股份有限公司 ISIN: TW0007754004 Shares Out.: Shares Outstanding: 100.728M¹ TV: TradingView: TPEX: 7754 SA: Stock Analysis: TPEX: 7754 YF: Yahoo Finance: 7754.TWO GF: Google Finance: TPEX: 7754 BA: Barron's: 7754 MS: Morningstar: ROCO: 7754	62.00 TWD	TV: TradingView: TPEX: 7754 SA: Stock Analysis: TPEX: 7754 YF: Yahoo Finance: 7754.TWO GF: Google Finance: TPEX: 7754 BA: Barron's: 7754 MS: Morningstar: ROCO: 7754

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About AnnJi Pharmaceutical Co., Ltd.

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.46B 172.76B TWD 3K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.61B 50.93B TWD 761%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.08B 34.04B TWD 475%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$726.25M 22.97B TWD 288%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$600.25M 18.98B TWD 221%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$571.26M 18.06B TWD 205%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 97K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 85K%	19.0	United States
argenx SE EBR: ARGX	$47.43B 41.39B EUR 25K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.23B 68.19T KRW 24K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.27B 60.27B AUD 22K%	29.3	Australia
Lonza Group AG SIX: LONN	$41.88B 33.71B CHF 22K%	37.2	Switzerland

chevron_leftBack